Virios Therapeutics Inc Stock

$2.55

5.90%

Nasdaq, Nov 22, 03:30 pm CET

ISIN

US92829J1043

Symbol

VIRI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Virios Therapeutics Inc Stock price

$2.68

-247.32 98.93% 5Y

Nasdaq, Closing price Mon, Nov 25 2024

+0.13 5.10%

ISIN

US92829J1043

Symbol

VIRI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$3.57m
Enterprise Value	$550.00k
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	0.95
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-4.80m
Free Cash Flow (TTM) Free Cash Flow	$-4.18m
Cash position	$3.02m
EPS (TTM) EPS	$-5.87
P/E forward	negative
Short interest	1.76%

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Get Started for Free Today

Virios Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

2 Analysts have issued a Virios Therapeutics Inc forecast:

1x Buy

50%

1x Hold

50%

More details on Analyst Estimates Including Price Targets

2 Analysts have issued a Virios Therapeutics Inc forecast:

Buy

50%

Hold

50%

Analyst Estimates with Stock Price Targets

Financial data from Virios Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	3.44 3.44	9% 9% -
- Research and Development Expense	1.35 1.35	66% 66% -
EBITDA	-4.80 -4.80	38% 38% -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-4.80 -4.80	38% 38% -
Net Profit	-4.68 -4.68	38% 38% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Virios Therapeutics Inc Stock News

Neutral

Business Wire

●

about 2 months ago

VIRI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Virios Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Virios Therapeutics, Inc. (NASDAQ: VIRI) and Sealbond Limited is fair to Virios shareholders. Halper Sadeh encourages Virios shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh....

Neutral

GlobeNewsWire

●

about 2 months ago

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

ATLANTA and VANCOUVER, British Columbia, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ: VIRI) (the “Company”), and Wex Pharmaceuticals, Inc. (“WEX”), a wholly owned subsidiary of CK Life Sciences Int'l., (Holdings) Inc. (“CKLS”), today announced that Virios has entered into a definitive share exchange agreement with Sealbond Limited, an indirect parent of Wex, pursuant to ...

Neutral

GlobeNewsWire

●

4 months ago

Virios Therapeutics Announces Second Quarter 2024 Financial Results

- Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) -

More Virios Therapeutics Inc News

Company Profile

Virios Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of antiviral therapies to treat diseases associated with a viral triggered abnormal immune response including fibromyalgia. It offers IMC-1 a novel, proprietary, fixed dose combination of famciclovir and celecoxib. The company was founded by William L. Pridgen on February 28, 2012 and is headquartered in Alpharetta, GA.

Head office	United States
CEO	Gregory Duncan
Employees	4
Founded	2012
Website	www.dwtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now